Related Experiment Videos

[Mono Mac 50D treatment results in patients with chronic coronary heart disease]

Klinicheskaia Meditsina
|October 20, 2001
PubMed

Insights

Mono Poppy 50mg effectively treated angina pectoris in patients post-bypass surgery, post-heart attack, and with stable angina. The medication improved physical tolerance and reduced nitroglycerin use with minimal side effects.

Area of Science:

  • Cardiology
  • Pharmacology

Background:

  • Angina pectoris significantly impacts patient quality of life and treatment outcomes.
  • Current therapeutic strategies for angina pectoris require optimization for efficacy and safety.

Purpose of the Study:

  • To evaluate the therapeutic efficiency and safety of Mono Poppy 50mg in patients with various forms of angina pectoris.
  • To assess the impact of Mono Poppy 50mg on physical tolerance and nitroglycerin dependency.

Main Methods:

  • A 3-month observational study involving 22 patients with angina pectoris.
  • Patients were categorized into three groups: post-coronary artery bypass grafting, post-myocardial infarction, and stable angina pectoris.
  • Dosage ranged from 25-50 mg/day, with regular monitoring of symptoms and medication use.

Main Results:

  • Mono Poppy 50mg demonstrated significant stabilization of condition in the majority of patients.
  • Patients experienced increased physical load tolerance and a marked reduction in nitroglycerin use (from an average of 8 to 2 per week).
  • Headache was the only noted side effect in one patient, requiring a dose reduction.

Conclusions:

  • Mono Poppy 50mg exhibits favorable efficacy and safety profiles for managing angina pectoris.
  • The drug can potentially reduce reliance on other anti-anginal medications, thereby decreasing overall treatment burden and cost.
  • Mono Poppy 50mg offers a valuable therapeutic option for diverse angina pectoris patient populations.

Related Concept Videos